Redx, a provider of translational research capacity and experience in cancer stem cells, tumor immunology and anti-microbial resistance, and Pierre Fabre Research Institute (IRPF) have formed an agreement for cancer research. The exclusive deal will see Redx and IRPF work together on the evaluation and development of a small molecule program for an undisclosed oncology target. Following the first stage of the collaboration, IRPF will have the option to enter into exclusive negotiations to license global rights for the program in selected cancer indications.

Financial terms have not been disclosed, but Redx Pharma chief executive Neil Murray described the deal as a highly significant milestone in the company's development.

The Redx Pharma group is focused on early stage drug discovery and development programs at sites in Liverpool (Redx Oncology) and at Alderley Park, Cheshire (Redx Anti-Infectives).

Pierre Fabre, a French pharmaceutical company, has experience in both oncology and dermatology. Its portfolio focuses on chemotherapies, monoclonal antibodies, immuno-conjugates assets at various development phases and several value-added dermatological drugs, including dedicated products for orphan and debilitating conditions such as infantile hemangiomas. The pipeline has been reinforced recently with a licensing agreement for a new cancer therapeutic in immuno-oncology, AUNP12, an immune checkpoint modulator targeting the PD-1 pathway.

Neil Murray, chief executive of Redx Pharma, said, “The collaboration demonstrates the potential of our oncology pipeline to deliver novel cancer therapeutics which all concerned hope will generate significant patient benefits.”